{"id":4169,"date":"2023-12-22T06:30:40","date_gmt":"2023-12-22T11:30:40","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/"},"modified":"2026-09-24T00:05:52","modified_gmt":"2026-09-24T04:05:52","slug":"gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/","title":{"rendered":"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 22 d\u00e9cembre 2023, 7h30 CET <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN\u00a0:\u00a0FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0<strong>Soci\u00e9t\u00e9<\/strong>\u00ab\u00a0), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives r\u00e9tiniennes et les troubles du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Laurence Rodriguez poss\u00e8de plus de 30 ans d\u2019exp\u00e9rience dans le secteur des sciences de la vie, dont 13 ans dans le secteur des maladies rares chez Sanofi Genzyme, o\u00f9 elle a occup\u00e9 diverses fonctions ex\u00e9cutives. En tant que Directrice de l\u2019entit\u00e9 \u00ab Maladies rares et maladies h\u00e9matologiques rares\u00a0\u00bb chez Sanofi Genzyme, elle a supervis\u00e9 le lancement r\u00e9ussi de nombreux traitements, d\u00e9velopp\u00e9s en interne ou r\u00e9sultant d\u2019acquisitions. Elle a rejoint GenSight Biologics en mai 2021, en tant que Directrice des Op\u00e9rations pour la France. Elle a ainsi g\u00e9r\u00e9 le programme d\u2019acc\u00e8s pr\u00e9coce en vue de la commercialisation de LUMEVOQ<sup>\u00ae<\/sup> et cr\u00e9\u00e9 des relations solides et de confiance avec les diff\u00e9rentes parties prenantes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Laurence Rodriguez<\/strong>, Directrice G\u00e9n\u00e9rale a comment\u00e9 :\u00a0\u00ab\u00a0<em>De nombreux malades atteints de la neuropathie optique h\u00e9r\u00e9ditaire de Leber attendent de pouvoir b\u00e9n\u00e9ficier de <\/em>LUMEVOQ<sup>\u00ae<\/sup><em>. Plus de 200 patients ont d\u00e9j\u00e0 b\u00e9n\u00e9fici\u00e9 de ce produit, qui r\u00e9pond \u00e0 un besoin m\u00e9dical non couvert majeur. Je mesure ainsi ma responsabilit\u00e9 et celle de l\u2019\u00e9quipe \u00e0 mettre tout en \u0153uvre pour amener ce traitement au march\u00e9 dans les meilleurs d\u00e9lais. Mon exp\u00e9rience et les relations de confiance nou\u00e9es avec les parties prenantes me permettront d\u2019effectuer un d\u00e9part lanc\u00e9, et soutiendront un solide plan d\u2019action<\/em>.\u00a0\u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab\u00a0<em>L&rsquo;exp\u00e9rience de Laurence, tant chez GenSight, que dans le domaine des m\u00e9dicaments orphelins, est impressionnante. Nous sommes impatients de travailler avec Laurence pour transformer GenSight,<\/em>\u00a0\u00bb a d\u00e9clar\u00e9 <strong>Michael Wyzga<\/strong>, Pr\u00e9sident du conseil d\u2019administration.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Laurence Rodriguez d\u00e9tient un dipl\u00f4me d\u2019Etat de nutrition et biochimie et une ma\u00eetrise de Sciences Po Paris, et a suivi un programme de leadership organisationnel \u00e0 la Harvard Business School.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le conseil d&rsquo;administration tient \u00e0 remercier Bernard Gilly, co-fondateur de la Soci\u00e9t\u00e9 en 2012 aux c\u00f4t\u00e9s du Pr. Jos\u00e9-Alain Sahel, pour ses nombreuses ann\u00e9es de d\u00e9vouement au sein de la Soci\u00e9t\u00e9, et sa contribution essentielle pour faire de LUMEVOQ<sup>\u00ae<\/sup> une th\u00e9rapie capable de transformer la vie des patients. Il restera administrateur de la Soci\u00e9t\u00e9 bien que n&rsquo;assumant plus de responsabilit\u00e9s op\u00e9rationnelles.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 22 d\u00e9cembre 2023, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN\u00a0:\u00a0FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0Soci\u00e9t\u00e9\u00ab\u00a0), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives r\u00e9tiniennes et les troubles du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76],"post-year":[],"class_list":["post-4169","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 22 d\u00e9cembre 2023, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN\u00a0:\u00a0FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0Soci\u00e9t\u00e9\u00ab\u00a0), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives r\u00e9tiniennes et les troubles du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-22T11:30:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:52+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale\",\"datePublished\":\"2023-12-22T11:30:40+00:00\",\"dateModified\":\"2026-09-24T04:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/\"},\"wordCount\":457,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/\",\"name\":\"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2023-12-22T11:30:40+00:00\",\"dateModified\":\"2026-09-24T04:05:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/12\\\/22\\\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale - GenSight Biologics","og_description":"Paris, France, le 22 d\u00e9cembre 2023, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN\u00a0:\u00a0FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0Soci\u00e9t\u00e9\u00ab\u00a0), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives r\u00e9tiniennes et les troubles du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/","og_site_name":"GenSight Biologics","article_published_time":"2023-12-22T11:30:40+00:00","article_modified_time":"2026-09-24T04:05:52+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale","datePublished":"2023-12-22T11:30:40+00:00","dateModified":"2026-09-24T04:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/"},"wordCount":457,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/","name":"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2023-12-22T11:30:40+00:00","dateModified":"2026-09-24T04:05:52+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/12\/22\/gensight-biologics-annonce-la-nomination-de-laurence-rodriguez-en-qualite-de-directrice-generale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce la nomination de Laurence Rodriguez en qualit\u00e9 de Directrice G\u00e9n\u00e9rale"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4169"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4169"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4169"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4169"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4169"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}